BRIDGEWATER, N.J., Jan. 10, 2022 /PRNewswire/ — NovoPath LLC, a leader in laboratory information systems, today announced the release and availability of NovoPath 360, a next-generation LIS platform that provides diagnostic labs process automation, robust tools, and seamless interoperability to accurately diagnose cases faster.
The NovoPath 360 platform, redefines laboratory information systems offering anatomic, clinical, and molecular Software as a Service (SaaS) solutions. The LIS platform hosts one-of-a-kind capabilities and interoperability to accession, diagnose, and generate fully customizable reports faster than ever. In turn, providing labs a way to leave behind all the unnecessary hassle of maintaining, updating, or fixing traditional on-premises software.
“Here at NovoPath we know behind each case is a person and their family worrying and waiting for results. Which truly means every second counts.”
“NovoPath 360 alleviates some of that worry and pain for patients by speeding up the diagnostic process as fast as possible. I am very proud of the NovoPath team and how we’re able to contribute is such a way is that truly does make a difference and empowers today’s modern labs.” – Promise Okeke, CEO, NovoPath LLC.
A Robust, Scalable Platform
Designed with the help of top pathologists, lab directors and techs, NovoPath 360 spans all aspects of the laboratory. The LIS platform addresses regulatory issues, improves efficiency, reduces errors, and assists with reimbursements.
Built to scale, the platform can be implemented at a single location and easily accommodate new locations and specializes as labs grow.
Over the past 25 years, NovoPath has built a reputation around their capabilities, NovoPath 360 continues the tradition of providing innovative capabilities. For a full list of capabilities, visit NovoPath.com
Seamless Interoperability
When combined with the NovoPath Interoperability Platform, NovoPath DXE, NovoPath 360 provides end-to-end seamless connectivity to registers, payers, hospitals, and other labs. The plug-and-play platform allows labs to easily connect to more than 150 existing EMRs and support thousands of simultaneous connections, ensuring data is securely getting where it needs to be.
The NovoPath Interoperability platform complies with all relevant privacy laws, enabling labs to create their own data exchange without putting patient data at risk.
Software as a Service Delivery Model
Provided through a software as a service (SaaS) delivery model, NovoPath 360 provides all the benefits of a robust LIS without the heavy load and stress traditional on-premises system carry with them.
NovoPath 360 removes the need to install applications on computers or data centers, in turn eliminating the cost and expense of hardware acquisition, customization, and maintenance.
“The pressures diagnostic labs face is continued to increase, while at the very same time reimbursements decrease. Offering NovoPath 360 as a SaaS solution reduces the cost of ownership while creating more value for the lab.” – Promise Okeke, CEO, NovoPath LLC.
About NovoPath LLC
NovoPath, 2021 Frost and Sullivan award winners for innovation is redefining laboratory information systems. NovoPath 360, SaaS-based platform enables anatomic and clinical pathology labs around the world to automate, track, simplify and complete complex cases from heme to derm faster than ever before.
We are raising the bar with one-of-a-kind capabilities helping labs accession, diagnose and generate fully customizable reports faster. Our clients are increasing their caseloads, reducing operating costs and establishing customer loyalty.
See how the labs of tomorrow are operating with NovoPath at www.NovoPath.com
Media contact:
Dayna Carlin
327112@email4pr.com
7346580973
View original content to download multimedia:https://www.prnewswire.com/news-releases/novopath-llc-redefines-laboratory-information-systems-with-2022-release-of-novopath-360-301455771.html
SOURCE NovoPath LLC
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…